Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoRa study of dolutegravir versus raltegravir for HIV post-exposure prophylaxis tolerability
NL-OMON26416Unknown
- Sponsor
- University Medical Center Utrecht
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dolutegravir, raltegravir, tenofovir disoproxil fumarate, emtricitabine and lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Grade 2 to 4 neurocognitive adverse events, Brief Symptom Inventory score and 2 more. Status: unknown.
02
Drugs
dolutegravirraltegravirtenofovir disoproxil fumarateemtricitabinelamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON26416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26416.